Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2019, Vol. 10 Issue (2) : 353-366     DOI: 10.14336/AD.2018.0617
Review Article |
MicroRNAs or Long Noncoding RNAs in Diagnosis and Prognosis of Coronary Artery Disease
Yuan Zhang*, Lei Zhang, Yu Wang, Han Ding, Sheng Xue, Hongzhao Qi, Peifeng Li*
Institute for Translational Medicine, Qingdao University, Deng Zhou Road 38, Qingdao 266021, China
Download: PDF(498 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Coronary artery disease (CAD) is the result of atherosclerotic plaque development in the wall of the coronary arteries. The underlying mechanism involves atherosclerosis of the arteries of the heart which is a relatively complex process comprising several steps. In CAD, atherosclerosis induces functional and structural changes. The pathogenesis of CAD results from various changes in and interactions between multiple cell types in the artery walls; these changes mainly include endothelial cell (EC) dysfunction, vascular smooth muscle cell (SMC) alteration, lipid deposition and macrophage activation. Various blood markers associated with an increased risk for cardiovascular endpoints have been identified; however, few have yet been shown to have a diagnostic impact or important clinical implications that would affect patient management. Noncoding RNAs, especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), can be stable in plasma and other body fluids and could therefore serve as biomarkers for some diseases. Many studies have shown that some miRNAs and lncRNAs play key roles in heart and vascular development and in cardiac pathophysiology. Thus, we summarize here the latest research progress, focusing on the molecular mechanism of miRNAs and lncRNAs in CAD, with the intent of seeking new targets for the treatment of heart disease.

Keywords miRNAs      lncRNAs      coronary artery disease      atherosclerotic plaque     
Corresponding Authors: Zhang Yuan,Li Peifeng   
About author:

These authors contributed equally to this study.

Issue Date: 12 February 2018
E-mail this article
E-mail Alert
Articles by authors
Yuan Zhang
Lei Zhang
Yu Wang
Han Ding
Sheng Xue
Hongzhao Qi
Peifeng Li
Cite this article:   
Yuan Zhang,Lei Zhang,Yu Wang, et al. MicroRNAs or Long Noncoding RNAs in Diagnosis and Prognosis of Coronary Artery Disease[J]. Aging and disease, 2019, 10(2): 353-366.
URL:     OR
ClassificationsMiRNAsCell type/processDysfunction typeExpressionFunctionsRefs
ECs/VSMCs functionmiR-126-5pPlasma/ ECsRegulationDown-regulatedplay the role of anti-atherogenisis and enhance ECs repair[27, 28]
miR-17-92 cluster (miR-17, miR-18a, miR-20a, miR-19a/b)Plasma/ ECsRegulationDown-regulatedattenuate TNF-α-induced endothelial cell apoptosis[29, 30]
miR-206VSMCs/ plasmaRegulationUp-regulatedanti-atherosclerosis by inhibiting the expression of FOXP1 in VSMCs[31, 32]
miR-574-5pVSMCs/ plasmaExpressionUp-regulatedpromote cell proliferation and inhibits apoptosis by inhibiting ZDHHC14 gene expression[34]
miR-23aECsRegulationDown-regulatedsuppress cellular migration and vasculogenesis via targeting EGFR[35, 37]
miR-21VSMCsRegulationUp-regulatedpromote aberrant VSMCs proliferation[35, 36]
miR-361-5pPlasma/ ECsRegulationUp-regulatedsuppress VEGF expression and EPCs activity[37]
InflammatorymiR-146aECsRegulationUp-regulatedinhibit the expression of adhesion molecules and inflammatory cytokines[40, 41]
miR-10aECsRegulationDown-regulatedregulate inflammatory responses[42, 43]
RegulationDown-regulatedfunction as anti-angiogenesis via suppression of AT1R and promote inflammatory signal transduction[44, 45]
miR-22PBMCsRegulationDown-regulatedanti-inflammatory response by targeting MCP-1[46]
Lipid metabolismmiR-486, miR-92aPlasma/ ECsRegulationUp-regulatedparticipate in HDL biogenesis[47, 48]
miR-24, miR-103aPBMCsExpressionUp-regulatedparticipate in cholesterol synthesis/transport and fatty acid metabolism[49]
miR-208aPlasma/ ECsRegulationUp-regulatedregulate cardiac hemostasis and lipid metabolism[51]
miR-370, miR-122PlasmaRegulationUp-regulatedregulate cholesterol and fatty-acid metabolism[51, 52]
miR-93Serum/ ECsRegulationUp-regulatedregulate serum cholesterol level via targeting ABCA1[52]
miR-33aSerum/ ECs macropahgeRegulationUp-regulatedregulate cholesterol accumulation by affecting HDL biogenesis[50]
miR-17-5pPlasma/ macropahgeExpressionUp-regulatedattenuate atherosclerotic lesion by mediating autophagy pathway and regulate cholesterol efflux[53, 54]
Platelet functionmiRNA-223, miRNA-197SerumRegulationUp-regulatedregulate thrombocyte activation[55, 56]
miR-624*, miR-340*PlateletExpressionUp-regulatedgovern platelet reactivity[57]
Circulating miRNAsmiR-126Circulating MVsRegulationDown-regulatedregulate the proliferation and migration of ECs[25]
miR-199aCardiomyocyte/ MVsRegulationDown-regulatedact as a suppressor of cardiomyocyte autophagy[25]
miR-222Endothelial MPsRegulationDown-regulatedanti-inflammatory by inhibiting ICAM-1 expression[63]
miR-149, miR-424PlasmaExpressionDown-regulatedinhibit pro-inflammatory-induced angiogenesis[58, 59]
miR-765Plasma/ ECsExpressionUp-regulatedinfluence arterial stiffness through modulating apelin expression[58]
miR-487aSerumExpressionUp-regulatedinvolve in the occurrence of atherosclerosis by regulating TAB3 expression[61]
miR-502SerumExpressionUp-regulatedsuppress autophagy process and play an atheroprotective role[61]
miR-215Serum/ ECsExpressionUp-regulatedstimulate neointimal lesion formation[61]
miR-29bSerum/ ECsExpressionDown-regulatedregulate myocardial ischemia and cardiac remodeling[62]
miR-145Plasma/VSMCsRegulationDown-regulatedplay a role in VSMCs phenotypic modulation[44]
let-7cPlasma/ECsRegulationDown-regulatedregulate cell differentiation and promote ECs apoptosis by inhibiting of Bcl-xl[44. 60]
Table 1  Summary of coronary artery disease-related miRNAs.
ClassificationsLncRNAsCelltype/processAction modeExpressionFunctionsRefs
ECs/VSMCs functionANRILVSMCAntisenseDown-regulatedregulate expression of CDKN2B and modulate VSMCs proliferation[67, 68]
H19PBMCs/ VSMCs/PlasmaAntisenseUp-regulatedfunction as a sponge of the let-7 to protect VSMCs[69-71]
HIF1a-AS1ECs/VSMCsAntisenseUp-regulatedpartake in process of atherosclerosis through controlling VSMCs and ECs apoptosis[72, 73]
LincRNA-p21ECs/VSMCsLincRNADown-regulateda novel regulator of neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity[74, 75]
RNCR3ECs/ VSMCsLincRNAUp-regulatednegatively regulate hypercholesterolemia and inflammatory factor releases, suppress apoptosis of ECs and VSMCs[76]
TGFB2-OT1ECs/VSMCsceRNAUp-regulatedregulate autophagy in ECs and VSMCs[77]
Lnc-Ang362VSMCsIntronic lncRNAUp-regulatedcoregulate in response to Ang II to regulate VSMCs proliferation[78]
HAS2-AS1VSMCsAntisenseUp-regulatedstabilize or augment the expression of HAS2 mRNA involved in neointimal hyperplasia and inflammation[79]
SMILRVSMCslincRNAUp-regulatedremodel of the extracellular matrix and neointimal formation, and inflammation[80]
SENCRECsAntisenseDown-regulatedregulate endothelial differentiation and angiogenesis[81]
MEG3ECsIntronic lncRNADown-regulatedregulate endothelial differentiation[82]
InflammatoryLincRNA-Cox2ECslincRNAUp-regulatedpromote inflammatory gene transcription in macrophages[84]
MKI67IP-3ECsceRNADown-regulatednegatively regulate let-7e to regulate endothelial function and inflammation[85]
LncRNA-letheMacrophagesceRNADown-regulatednegatively regulate NF-kB expression[86]
Lipid metabolismLincRNA-DYNLRB2-2MacrophageslincRNAUp-regulatedpromote ABCA1-mediated inflammation and cholesterol efflux in foam cells[87]
RP5-833A20.1MacrophagesAntisenseDown-regulatedregulate cholesterol homeostasis and inflammatory reactions through inhibit NFIA expression[88]
APOA1-ASPlasmaAntisenseUp-regulatedinhibit the expression of APOA1 and the formation of HDL[89]
HOTAIRMacrophages/ ECsAntisenseDown-regulatedattenuate the suppression of cell viability and enhancement of cell apoptosis caused by ox-LDL[91, 92]
Circulating lncRNAsCoroMarkerPlasma/
LncRNAUp-regulateddecrease pro-inflammatory cytokine secretion from THP-1 monocytic cells[93, 94]
LncPPARδPBMCsLncRNAUp-regulatedregulate the expression of PPARδ to mediate inflammatory response[95]
LIPCARPlasmaMitochondrial lncRNAUp-regulatedregulate mitochondrial pathways of oxidative phosphorylation and inflammasome activation[71, 96]
Table 2  Summary of coronary artery disease-related lncRNAs.
[1] Sakellarios A, Raeber L, Bourantas C, Exarchos T, Athanasiou L, Pelosi G, et al. (2016). Prediction of Atherosclerotic Plaque Development in an in Vivo Coronary Arterial Segment Based on a Multi-level Modeling Approach. IEEE Trans Biomed Eng.
[2] Weber C, Noels H (2011). Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 17:1410-1422.
[3] Matsuzawa Y, Lerman A (2014). Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis, 25:713-724.
[4] Ding L, Su XX, Zhang WH, Xu YX, Pan XF (2017). Gene Expressions Underlying Mishandled Calcium Clearance and Elevated Generation of Reactive Oxygen Species in the Coronary Artery Smooth Muscle Cells of Chronic Heart Failure Rats. Chin Med J (Engl), 130:460-469.
[5] Nurnberg ST, Cheng K, Raiesdana A, Kundu R, Miller CL, Kim JB, et al. (2015). Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap. PLoS Genet, 11:e1005155.
[6] Hawkins MA (2004). Markers of increased cardiovascular risk: are we measuring the most appropriate parameters? Obes Res, 12 Suppl 2:107S-114S.
[7] Parizadeh SM, Ferns GA, Ghandehari M, Hassanian SM, Ghayour-Mobarhan M, Parizadeh SMR, et al. (2017). The diagnostic and prognostic value of circulating microRNAs in coronary artery disease: A novel approach to disease diagnosis of stable CAD and acute coronary syndrome. J Cell Physiol.
[8] McCarthy CP, McEvoy JW, Januzzi JLJr, (2018). Biomarkers in stable coronary artery disease. Am Heart J, 196:82-96.
[9] Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, et al. (2018). Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. Oncotarget, 9:17238-17254.
[10] Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, et al. (2017). Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J.
[11] Samanta S, Balasubramanian S, Rajasingh S, Patel U, Dhanasekaran A, Dawn B, et al. (2016). MicroRNA: A new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc Med, 26:407-419.
[12] Bayoumi AS, Sayed A, Broskova Z, Teoh JP, Wilson J, Su H, et al. (2016). Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci, 17:356.
[13] Gorodkin J, Hofacker IL (2011). From structure prediction to genomic screens for novel non-coding RNAs. PLoS Comput Biol, 7:e1002100.
[14] Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M (2014). Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics, 2014:970607.
[15] Wagschal A, Najafi-Shoushtari SH, Wang L, Goedeke L, Sinha S, deLemos AS, et al. (2015). Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med, 21:1290-1297.
[16] Novak J, Olejnickova V, Tkacova N, Santulli G (2015). Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol, 887:79-100.
[17] Feinberg MW, Moore KJ (2016). MicroRNA Regulation of Atherosclerosis. Circ Res, 118:703-720.
[18] Dey BK, Mueller AC, Dutta A (2014). Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription, 5:e944014.
[19] Cao J (2014). The functional role of long non-coding RNAs and epigenetics. Biol Proced Online, 16:11.
[20] Nishiguchi T, Imanishi T, Akasaka T (2015). MicroRNAs and cardiovascular diseases. Biomed Res Int, 2015:682857.
[21] Archer K, Broskova Z, Bayoumi AS, Teoh JP, Davila A, Tang Y, et al. (2015). Long Non-Coding RNAs as Master Regulators in Cardiovascular Diseases. Int J Mol Sci, 16:23651-23667.
[22] Bobryshev YV, Ivanova EA, Chistiakov DA, Nikiforov NG, Orekhov AN (2016). Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. Biomed Res Int, 2016:9582430.
[23] Strissel KJ, Denis GV, Nikolajczyk BS (2014). Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes, 21:330-338.
[24] Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, et al. (2014). MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc, 3:e001249.
[25] Gimbrone MAJr, Garcia-Cardena G (2016). Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res, 118:620-636.
[26] Li HY, Zhao X, Liu YZ, Meng Z, Wang D, Yang F, et al. (2016). Plasma MicroRNA-126-5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cell Physiol Biochem, 39:837-846.
[27] Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. (2014). MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med, 20:368-376.
[28] Tang Y, Zhang YC, Chen Y, Xiang Y, Shen CX, Li YG (2015). The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease. Sci Rep, 5:15132.
[29] Lin J, Xue A, Li L, Li B, Li Y, Shen Y, et al. (2016). MicroRNA-19b Downregulates Gap Junction Protein Alpha1 and Synergizes with MicroRNA-1 in Viral Myocarditis. Int J Mol Sci, 17.
[30] Zhou J, Shao G, Chen X, Yang X, Huang X, Peng P, et al. (2015). miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. Biosci Rep, 36:e00295.
[31] Wang M, Ji Y, Cai S, Ding W (2016). MiR-206 Suppresses the Progression of Coronary Artery Disease by Modulating Vascular Endothelial Growth Factor (VEGF) Expression. Med Sci Monit, 22:5011-5020.
[32] Xing T, Du L, Zhuang X, Zhang L, Hao J, Wang J (2017). Upregulation of microRNA-206 induces apoptosis of vascular smooth muscle cells and decreases risk of atherosclerosis through modulating FOXP1. Exp Ther Med, 14:4097-4103.
[33] Lai Z, Lin P, Weng X, Su J, Chen Y, He Y, et al. (2018). MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease. Biomed Pharmacother, 97:162-167.
[34] Han H, Qu G, Han C, Wang Y, Sun T, Li F, et al. (2015). MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Exp Mol Med, 47:e138.
[35] Hutcheson R, Chaplin J, Hutcheson B, Borthwick F, Proctor S, Gebb S, et al. (2014). miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome. FASEB J, 28:4088-4099.
[36] Wang HW, Lo HH, Chiu YL, Chang SJ, Huang PH, Liao KH, et al. (2014). Dysregulated miR-361-5p/VEGF axis in the plasma and endothelial progenitor cells of patients with coronary artery disease. PLoS One, 9:e98070.
[37] Galkina E, Ley K (2009). Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol, 27:165-197.
[38] Mudau M, Genis A, Lochner A, Strijdom H (2012). Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr, 23:222-231.
[39] Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, et al. (2015). Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-kappaB activation. J Cereb Blood Flow Metab, 35:412-423.
[40] Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. (2013). MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med, 5:1017-1034.
[41] Luo L, Chen B, Li S, Wei X, Liu T, Huang Y, et al. (2016). Plasma miR-10a: A Potential Biomarker for Coronary Artery Disease. Dis Markers, 2016:3841927.
[42] Fang Y, Shi C, Manduchi E, Civelek M, Davies PF (2010). MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A, 107:13450-13455.
[43] Faccini J, Ruidavets JB, Cordelier P, Martins F, Maoret JJ, Bongard V, et al. (2017). Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Sci Rep, 7:42916.
[44] Li X, Kong D, Chen H, Liu S, Hu H, Wu T, et al. (2016). miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1. Sci Rep, 6:21789.
[45] Chen B, Luo L, Zhu W, Wei X, Li S, Huang Y, et al. (2016). miR-22 contributes to the pathogenesis of patients with coronary artery disease by targeting MCP-1: An observational study. Medicine (Baltimore), 95:e4418.
[46] Niculescu LS, Simionescu N, Sanda GM, Carnuta MG, Stancu CS, Popescu AC, et al. (2015). MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients. PLoS One, 10:e0140958.
[47] Liu H, Li G, Zhao W, Hu Y (2016). Inhibition of MiR-92a May Protect Endothelial Cells After Acute Myocardial Infarction in Rats: Role of KLF2/4. Med Sci Monit, 22:2451-2462.
[48] Dong J, Liang YZ, Zhang J, Wu LJ, Wang S, Hua Q, et al. (2017). Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease. J Atheroscler Thromb, 24:430-441.
[49] Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramirez CM, et al. (2013). A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol, 33:2339-2352.
[50] Liu H, Yang N, Fei Z, Qiu J, Ma D, Liu X, et al. (2016). Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. Biomed Rep, 5:332-336.
[51] Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI (2010). MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res, 51:1513-1523.
[52] Chen J, Xu L, Hu Q, Yang S, Zhang B, Jiang H (2015). MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int J Cardiol, 197:123-124.
[53] Huang C, Yu XH, Zheng XL, Ou X, Tang CK (2018). Interferon-stimulated gene 15 promotes cholesterol efflux by activating autophagy via the miR-17-5p/Beclin-1 pathway in THP-1 macrophage-derived foam cells. Eur J Pharmacol, 827:13-21.
[54] Orenes-Pinero E, Marin F, Lip GY (2016). miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients. Ann Transl Med, 4:200.
[55] Shi R, Zhou X, Ji WJ, Zhang YY, Ma YQ, Zhang JQ, et al. (2015). The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. Biomed Res Int, 2015:981841.
[56] Sondermeijer BM, Bakker A, Halliani A, de Ronde MW, Marquart AA, Tijsen AJ, et al. (2011). Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One, 6:e25946.
[57] Ali Sheikh MS, Xia K, Li F, Deng X, Salma U, Deng H, et al. (2015). Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients. Biomed Res Int, 2015:740301.
[58] Lee A, Papangeli I, Park Y, Jeong HN, Choi J, Kang H, et al. (2017). A PPARgamma-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. Sci Rep, 7:2528.
[59] Banerjee S, Xie N, Cui H, Tan Z, Yang S, Icyuz M, et al. (2013). MicroRNA let-7c regulates macrophage polarization. J Immunol, 190:6542-6549.
[60] Wang J, Pei Y, Zhong Y, Jiang S, Shao J, Gong J (2014). Altered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease. PLoS One, 9:e107012.
[61] Yuan H, Ma J, Li T, Han X (2018). MiR-29b aggravates lipopolysaccharide-induced endothelial cells inflammatory damage by regulation of NF-kappaB and JNK signaling pathways. Biomed Pharmacother, 99:451-461.
[62] Jansen F, Yang X, Baumann K, Przybilla D, Schmitz T, Flender A, et al. (2015). Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med, 19:2202-2214.
[63] Li C, Li S, Zhang F, Wu M, Liang H, Song J, et al. (2018). Endothelial microparticles-mediated transfer of microRNA-19b promotes atherosclerosis via activating perivascular adipose tissue inflammation in apoE(-/-) mice. Biochem Biophys Res Commun, 495:1922-1929.
[64] Jain S, Thakkar N, Chhatai J, Pal Bhadra M, Bhadra U (2017). Long non-coding RNA: Functional agent for disease traits. RNA Biol, 14:522-535.
[65] Li H, Zhu H, Ge J (2016). Long Noncoding RNA: Recent Updates in Atherosclerosis. Int J Biol Sci, 12:898-910.
[66] Zhuang J, Peng W, Li H, Wang W, Wei Y, Li W, et al. (2012). Methylation of p15INK4b and expression of ANRIL on chromosome 9p21 are associated with coronary artery disease. PLoS One, 7:e47193.
[67] Zhou X, Han X, Wittfeldt A, Sun J, Liu C, Wang X, et al. (2016). Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-kappaB pathway. RNA Biol, 13:98-108.
[68] Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. (2013). The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell, 52:101-112.
[69] Gao Y, Wu F, Zhou J, Yan L, Jurczak MJ, Lee HY, et al. (2014). The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res, 42:13799-13811.
[70] Zhang Z, Gao W, Long QQ, Zhang J, Li YF, Liu DC, et al. (2017). Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep, 7:7491.
[71] Zhao Y, Feng G, Wang Y, Yue Y, Zhao W (2014). Regulation of apoptosis by long non-coding RNA HIF1A-AS1 in VSMCs: implications for TAA pathogenesis. Int J Clin Exp Pathol, 7:7643-7652.
[72] Wang J, Chen L, Li H, Yang J, Gong Z, Wang B, et al. (2015). Clopidogrel reduces apoptosis and promotes proliferation of human vascular endothelial cells induced by palmitic acid via suppression of the long non-coding RNA HIF1A-AS1 in vitro. Mol Cell Biochem, 404:203-210.
[73] Tang SS, Cheng J, Cai MY, Yang XL, Liu XG, Zheng BY, et al. (2016). Association of lincRNA-p21 Haplotype with Coronary Artery Disease in a Chinese Han Population. Dis Markers, 2016:9109743.
[74] Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, et al. (2014). LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation, 130:1452-1465.
[75] Shan K, Jiang Q, Wang XQ, Wang YN, Yang H, Yao MD, et al. (2016). Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis, 7:e2248.
[76] Huang S, Lu W, Ge D, Meng N, Li Y, Su L, et al. (2015). A new microRNA signal pathway regulated by long noncoding RNA TGFB2-OT1 in autophagy and inflammation of vascular endothelial cells. Autophagy, 11:2172-2183.
[77] Leung A, Trac C, Jin W, Lanting L, Akbany A, Saetrom P, et al. (2013). Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res, 113:266-278.
[78] Vigetti D, Deleonibus S, Moretto P, Bowen T, Fischer JW, Grandoch M, et al. (2014). Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation. J Biol Chem, 289:28816-28826.
[79] Ballantyne MD, Pinel K, Dakin R, Vesey AT, Diver L, Mackenzie R, et al. (2016). Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation. Circulation, 133:2050-2065.
[80] Boulberdaa M, Scott E, Ballantyne M, Garcia R, Descamps B, Angelini GD, et al. (2016). A Role for the Long Noncoding RNA SENCR in Commitment and Function of Endothelial Cells. Mol Ther, 24:978-990.
[81] Wu Z, He Y, Li D, Fang X, Shang T, Zhang H, et al. (2017). Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21. Am J Transl Res, 9:3326-3335.
[82] Lin J, Zhang X, Xue C, Zhang H, Shashaty MG, Gosai SJ, et al. (2015). The long noncoding RNA landscape in hypoxic and inflammatory renal epithelial injury. Am J Physiol Renal Physiol, 309:F901-913.
[83] Hu G, Gong AY, Wang Y, Ma S, Chen X, Chen J, et al. (2016). LincRNA-Cox2 Promotes Late Inflammatory Gene Transcription in Macrophages through Modulating SWI/SNF-Mediated Chromatin Remodeling. J Immunol, 196:2799-2808.
[84] Lin Z, Ge J, Wang Z, Ren J, Wang X, Xiong H, et al. (2017). Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci Rep, 7:42498.
[85] Zgheib C, Hodges MM, Hu J, Liechty KW, Xu J (2017). Long non-coding RNA Lethe regulates hyperglycemia-induced reactive oxygen species production in macrophages. PLoS One, 12:e0177453.
[86] Hu YW, Yang JY, Ma X, Chen ZP, Hu YR, Zhao JY, et al. (2014). A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res, 55:681-697.
[87] Hu YW, Zhao JY, Li SF, Huang JL, Qiu YR, Ma X, et al. (2015). RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. Arterioscler Thromb Vasc Biol, 35:87-101.
[88] Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, et al. (2014). Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep, 6:222-230.
[89] Huang C, Hu YW, Zhao JJ, Ma X, Zhang Y, Guo FX, et al. (2016). Long Noncoding RNA HOXC-AS1 Suppresses Ox-LDL-Induced Cholesterol Accumulation Through Promoting HOXC6 Expression in THP-1 Macrophages. DNA Cell Biol, 35:722-729.
[90] Peng Y, Meng K, Jiang L, Zhong Y, Yang Y, Lan Y, et al. (2017). Thymic stromal lymphopoietin-induced HOTAIR activation promotes endothelial cell proliferation and migration in atherosclerosis. Biosci Rep, 37.
[91] Wu H, Liu J, Li W, Liu G, Li Z (2016). LncRNA-HOTAIR promotes TNF-alpha production in cardiomyocytes of LPS-induced sepsis mice by activating NF-kappaB pathway. Biochem Biophys Res Commun, 471:240-246.
[92] Yang Y, Cai Y, Wu G, Chen X, Liu Y, Wang X, et al. (2015). Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond), 129:675-685.
[93] Cai Y, Yang Y, Chen X, Wu G, Zhang X, Liu Y, et al. (2016). Circulating 'lncRNA OTTHUMT00000387022' from monocytes as a novel biomarker for coronary artery disease. Cardiovasc Res, 112:714-724.
[94] Cai Y, Yang Y, Chen X, He D, Zhang X, Wen X, et al. (2016). Circulating "LncPPARdelta" From Monocytes as a Novel Biomarker for Coronary Artery Diseases. Medicine (Baltimore), 95:e2360.
[95] Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. (2014). Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res, 114:1569-1575.
[96] Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, et al. (2012). LincRNA-p21 suppresses target mRNA translation. Mol Cell, 47:648-655.
[97] Dey BK, Pfeifer K, Dutta A (2014). The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev, 28:491-501.
[1] Ghanam A.R., Xu Qianlan, Ke Shengwei, Azhar Muhammad, Cheng Qingyu, Song Xiaoyuan. Shining the Light on Senescence Associated LncRNAs[J]. Aging and disease, 2017, 8(2): 149-161.
[2] Francisco J. Félix-Redondo,Maria Grau,Daniel Fernández-Bergés. Cholesterol and Cardiovascular Disease in the Elderly. Facts and Gaps[J]. Aging and Disease, 2013, 4(3): 154-169.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd